Medpace Financial Statements
NASDAQ: MEDPHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Medpace revenue and earnings
In fiscal 2025, Medpace generated $2.53 billion in revenue, up 20.0% from fiscal 2024, its 10th consecutive year of revenue growth. Net income was $451.1 million (+11.6% year over year), for a net margin of 17.8% versus a median of 15.9% in the prior 5 years. Operating margin was 21.1%.
Diluted earnings per share came in at $15.28, up from $12.63. Over the last 5 fiscal years, MEDP's revenue has grown at a 22.3% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Medpace income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.53B | 2.11B | 1.89B | 1.46B | 1.14B | 925.92M | 860.97M | 704.59M | 436.15M | 421.58M |
| Revenue growth (YoY) | +19.97% | +11.84% | +29.17% | +27.80% | +23.38% | +7.54% | +22.19% | +61.55% | +3.46% | +17.41% |
| Selling, General & Admin | 197.56M | 180.18M | 161.35M | 131.40M | 108.42M | 92.16M | 95.25M | 75.68M | 63.36M | 61.51M |
| Operating Income | 534.93M | 446.87M | 336.82M | 278.70M | 198.62M | 167.04M | 127.26M | 101.05M | 64.86M | 52.49M |
| Other Income (Expense) | 7.44M | 29.05M | -1.14M | 4.16M | 3.24M | 1.49M | -2.43M | -7.10M | -7.91M | -30.53M |
| Pretax Income | 542.38M | 475.92M | 335.68M | 282.86M | 201.85M | 168.53M | 124.83M | 93.95M | 56.95M | 21.96M |
| Income Tax | 91.25M | 71.54M | 52.87M | 37.49M | 20.00M | 23.15M | 24.39M | 20.77M | 17.82M | 8.53M |
| Net Income | 451.12M | 404.39M | 282.81M | 245.37M | 181.85M | 145.38M | 100.44M | 73.19M | 39.12M | 13.43M |
| Net Income growth (YoY) | +11.56% | +42.99% | +15.26% | +34.93% | +25.08% | +44.74% | +37.25% | +87.07% | +191.41% | — |
| EPS (Basic) | 15.64 | 13.06 | 9.20 | 7.57 | 5.06 | 4.07 | 2.79 | 2.05 | 1.00 | 0.38 |
| EPS (Diluted) | 15.28 | 12.63 | 8.88 | 7.28 | 4.81 | 3.84 | 2.67 | 1.97 | 0.98 | 0.37 |
| Shares Outstanding (Basic) | 28.85M | 30.96M | 30.72M | 32.39M | 35.86M | 35.63M | 35.88M | 35.55M | 39.06M | 35.69M |
| Shares Outstanding (Diluted) | 29.53M | 32.01M | 31.84M | 33.67M | 37.70M | 37.71M | 37.58M | 36.91M | 39.84M | 36.33M |
| EBITDA | 562.11M | 474.68M | 360.95M | 297.69M | 214.62M | 178.69M | 135.62M | 110.29M | 73.43M | 59.93M |
| Operating Margin | 21.14% | 21.19% | 17.86% | 19.09% | 17.39% | 18.04% | 14.78% | 14.34% | 14.87% | 12.45% |
| Net Margin | 17.83% | 19.17% | 15.00% | 16.81% | 15.92% | 15.70% | 11.67% | 10.39% | 8.97% | 3.18% |
This table shows 10 annual periods of Medpace's income statement, from FY 2025 back to FY 2016, across 14 line items including revenue, selling, general & admin, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow MEDP's reporting calendar. What is a income statement?